This cycling of the response to estrogen between growth induction and suppression mediated by intermittent estrogen exposure and the resulting change in the level of ER has led to the suggestion that “pre-emptively switching between estrogen and estrogen deprivation therapies before resistant tumors emerge is an effective strategy for long-term control of tumor burden” [7]. This evidence concerns the gene ESR1 and neoplasm.